Chinese Journal of Mycology 2020, Vol. 15 Issue (5): 257-261.
Expert forum Next Articles
Expert group of consensus on the clinical application of Terbinafine
Received:2020-09-10
Online:2020-10-28
Published:2020-10-28
CLC Number:
Expert group of consensus on the clinical application of Terbinafine. Clinical Application of Terbinafine：Expert consensus[J]. Chinese Journal of Mycology, 2020, 15(5): 257-261.
Add to citation manager EndNote|Ris|BibTeX
URL: http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/
http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/Y2020/V15/I5/257
| [1] | Elewski BE. Mechanisms of action of systemic antifungal agents[J]. J Am Acad Dermatol, 1993,28(5 part 1):S28-S34. |
| [2] | Finlay AY. Global overview of lamisil[J]. Br J Dermatol,1994,130(Suppl 43):1-3. |
| [3] | Finlay AY. Pharmacokinetics of terbinafine in the nail[J]. Br J Dermatol, 1992,126(Suppl 39):28-32. |
| [4] | Zehender H, Cabiac MD, Denouël J, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites[J]. Drug Invest,1994,8(4):203-210. |
| [5] | Balfour JA, Faulds D.Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses[J].Drugs, 1992,43(2):259-284. |
| [6] | 陈铁锋,余细勇,林曙光,等.盐酸特比萘芬凝胶的透皮吸收[J].中国现代应用药学,2004,21(S2):48-50. |
| [7] | Ryder NS. Terbinafine:mode of action and properties of the squalene epoxidase inhibition[J]. Br J Dermatol, 1992,126(Suppl 39):2-7. |
| [8] | Roberts DT.Oral terbinafine (lamisil) in the treatment of fungal infections of the skin and nails[J]. Dermatology, 1997,194(Suppl 1):37-39. |
| [9] | Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro[J]. Antimicrob Agents Chemother, 1987,31(9):1365-1368. |
| [10] | 燕华玲,王爱平,万喆,等.特比萘芬对白念珠菌菌丝相和酵母相敏感性的比较[J].中华皮肤科杂志,2005,38(8):515. |
| [11] | Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine[J]. BMJ, 1992,304:1151-1154. |
| [12] | van der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis[J]. Br J Dermatol,1992,126(Suppl 39):36-39. |
| [13] | Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine[J]. Br J Dermatol, 1992,126(Suppl 39):40-46. |
| [14] | McClellan KJ, Wiseman LR,Markham A. Terbinafine:An update of its use in superficial mycoses[J]. Drugs, 1999,58(1):179-202. |
| [15] | Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus[J]. J Eur Acad Dermatol Venereol, 2006, 20(10):1188-1193. |
| [16] | Nandwani R, Parnell A, Youle M, et al.Use of terbinafine in HIV-positive subjects:pilot studies in onychomycosis and oral candidiasis[J]. Br J Dermatol, 1996,134(Suppl 46):22-24:discussion 39. |
| [17] | Gupta AK, Lynch LE, Kogan N,et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2009, 23(3):256-262. |
| [18] | Gupta AK, Sibbald RG, AndriessenA,et al.Toenail onychomycosis-a Canadian approach with a new transungual treatment:development of a clinical pathway[J]. J Cutan Med Surg, 2015, 19(5):440-449. |
| [19] | Carrillo-Muñoz AJ, Giusiano G, Cárdenes D, et al.Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis[J]. Int J Antimicrob Agents, 2008,31(6):540-543. |
| [20] | Ranawaka RR, Nagahawatte A, Gunasekara TA,et al.Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis:A study with 90 patients[J]. J Dermatolog Treat, 2016,27(4):364-372. |
| [21] | Evans EGV. Resistance of Candida species to antifungal agents used in the treatment of onychomycosis:a review of current problems[J]. Br J Dermatol, 1999,141(Suppl 56):33-35. |
| [22] | 中国头癣诊疗指南工作组.中国头癣诊断和治疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):4-6. |
| [23] | Drago L, Micali G, Papini M, et al. Management of mycoses in daily practice[J].G Ital Dermatol Venereol, 2017, 152(6):642-650. |
| [24] | Kakourou T, Uksal U, European Society for Pediatric Dermatology.Guidelines for the management of tinea capitis in children[J]. Pediatr Dermatol, 2010,27(3):226-228. |
| [25] | Haroon TS, Hussain I, Mahmood A, etal. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis[J]. Br J Dennatol, 1992,126(Suppl 39):47-50. |
| [26] | Leung AKC, Hon KL, Leong KF,et al.Tinea capitis:An updated review[J].Recent Pat Inflamm Allergy Drug Discov, 2020,14(1):58-68. |
| [27] | Gupta AK, Mays RR, Versteeg SG,et al. Tinea capitis in children:a systematic review of management[J]. J Eur Acad Dermatol Venereol, 2018, 32(12):2264-2274. |
| [28] | Chen X, Jiang X, Yang M,et al.Systemic antifungal therapy for tinea capitis in children[J]. Cochrane Database Syst Rev, 2016,(5):CD004685. |
| [29] | Shwayder T.Terbinafine[J]. J Am Acad Dermatol, 1998,39(1):136. |
| [30] | 中国体癣和股癣诊疗指南工作组.中国体癣和股癣诊疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):1-3. |
| [31] | 中国中西医结合学会皮肤性病专业委员会真菌学组,中国医师协会皮肤科分会真菌亚专业委员会,中华医学会皮肤病分会真菌学组.手癣和足癣诊疗指南(2017修订版)[J].中国真菌学杂志,2017,12(6):321-324. |
| [32] | Shi TW, Zhang JA, Zhang XW, et al.Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis[J]. Mycoses, 2014,57(9):560-564. |
| [33] | Balfour JA, Faulds D.Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses[J].Drugs, 1992,43(2):259-284. |
| [34] | 刘耕,于波.盐酸特比萘芬阴道泡腾片治疗念珠菌性阴道炎疗效观察[J].中国真菌学杂志,2006,1(6):41-42. |
| [35] | 秦晓华,王明贵,Kanafani ZA,等.抗真菌药物的耐药机制及其临床意义[J]. 中国感染与化疗杂志,2010,10(4):320. |
| [36] | 38-Rex JH, Pfaller MA.Has antifungal susceptibility testing come of age[J]? Clin Infect Dis, 2002, 35(8):982-989. |
| [37] | Guanziroli E, Pavia G, Guttadauro A, et al. Deep dermatophytosis caused by Trichophyton verrucosum in an immunosuppressed patient:successful outcome with terbinafine[J]. Mycopathologia, 2019, 184(4):543-545. |
| [38] | Boral H, Durdu M, Ilkit M. Majocchi's granuloma:current perspectives[J]. Infect Drug Resist, 2018,11:751-760. |
| [39] | Wang X, Yang Y, Li R, et al. Two cases of dermatophytic granuloma successfully treated with terbinafine[J]. Mycopathologia, 2018, 183(3):611-614. |
| [40] | Zhou S, Yang Y, Liu K, et al. A case report of widespread Majocchi's granuloma in a patient with systemic lupus erythematosus[J]. Mycopathologia, 2017, 182(5-6):577-581. |
| [41] | Mahajan VK.Sporotrichosis:an overview and therapeutic options[J]. Dermatol Res Pract, 2014, 2014:272376. |
| [42] | 中华医学会皮肤性病学分会真菌学组,中国医师协会皮肤科医师分会医学真菌亚专业委员会,中西医结合学会皮肤性病专业委员会真菌学组. 孢子丝菌病诊疗指南[J]. 中华皮肤科杂志,2016, 49(7):456-459. |
| [43] | Francesconi G, Valle AC, Passos S, et al.Terbinafine (250 mg/day):an effective and, safe treatment of cutaneous sporotrichosis[J]. J Eur Acad Dermatol Venereol, 2009, 23(11):1273-1276. |
| [44] | Francesconi G, Francesconi do Valle AC, Passos SL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis[J]. Mycopathologia, 2011, 171(5):349-354. |
| [45] | Chapman SW, Pappas P, Kauffmann C,et al.Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis[J]. Mycoses, 2004, 47(1-2):62-68. |
| [46] | Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine[J]. Br J Dermatol, 1992, 126(Suppl 39):51-55. |
| [47] | Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis[J]. Clin Microbiol Rev, 2017,30(1):233-276. |
| [48] | Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation:Part II Lactation[J]. J Am Acad Dermatol, 2014, 70(3):417.e1-10; quiz 427. |
| [49] | Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration[J].J Dermatolog Treat,2020:1-5. |
| [50] | Stolmeier DA, Stratman HB, McIntee TJ,et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections[J]. JAMA Dermatol, 2018, 154(12):1409-1416. |
| [51] | Patel D,Castelo-Soccio LA, Rubin AI,et al. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis[J]. JAMA Dermatol, 2017,153(12):1326-1327. |
| [52] | García Rodríguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs[J]. Br J Clin Pharmacol, 1999,48(6):847-852. |
| [53] | Kantarc?o?lu B, Türköz HK, Y?lmaz G, et al. Aplastic anemia associated with oral terbinafine:a case report and review of the literature[J]. Turk J Haematol, 2014,31(4):411-416. |
| [54] | Gupta AK, Soori GS, Del Rosso JQ, et al. Severe neutropenia associated with oral terbinafine therapy[J]. J Am Acad Dermatol, 1998,38(5 Pt 1):765-767. |
| [55] | Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions[J]. Drug Metab Dispos,1999,27(9):1029-1038. |
| [1] | ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of subcutaneous and deep mycosis [J]. Chinese Journal of Mycology, 2020, 15(6): 374-377. |
| [2] | ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of superficial mycosis [J]. Chinese Journal of Mycology, 2020, 15(5): 297-303. |
| [3] | QU Xin-yao, LI Shan-shan, QU Yue, Abdulhakim Salad Nageye, SONG Yang, CUI Yan. In vitro antifungal susceptibility of 10 Chinese herbal monomers against Sporothrix globosa [J]. Chinese Journal of Mycology, 2020, 15(3): 145-149. |
| [4] | . [J]. Chinese Journal of Mycology, 2020, 15(3): 179-182. |
| [5] | ZHANG Juan, LI Xiao-hui, Feng Xue-ling, ZHANG Jing-jing. Study on the antifungal effect of Aspergillus fumigatus, Trichophyton mentogrophtes and Cryptococcus neoformans to alkaloids from Sophora alopecuroides [J]. Chinese Journal of Mycology, 2020, 15(2): 72-77. |
| [6] | LIU Guang-rong, ZHAI Chun-tao, JIN Min-rong, LI Cheng-liang. The inhibitory effects of natural antibacterial agent on 5 pathogenic microorganisms [J]. Chinese Journal of Mycology, 2020, 15(2): 88-92. |
| [7] | TAN Jing-wen, XU Hong, SONG Jin-feng, GAO Zhi-qin, YANG Hong, YANG Lian-juan, WEN Hai. In vitro antifungal susceptibility of polyhexamethylene biguanide against common superficial fungal species [J]. Chinese Journal of Mycology, 2020, 15(2): 93-96. |
| [8] | ZHU Hong-mei, WEN Hai, LI Bin. Advance on Traditional Chinese Herb in the topical antifungal therapy [J]. Chinese Journal of Mycology, 2019, 14(5): 316-320. |
| [9] | YU Shu-ying, ZHANG Li, LI Ying, XU Ying-chun. Evaluation of the in vitro antifungal activity of the domestic caspofungin against clinical Aspergillus isolates [J]. Chinese Journal of Mycology, 2019, 14(3): 141-146. |
| [10] | LIU Fei-fei, WANG Yan, CHEN Rong, SHEN Jian-zhen. Clinical efficacy and safety of intravenous injection voriconazole and fluconazole in preventing fungal infection in China: A meta analysis [J]. Chinese Journal of Mycology, 2019, 14(3): 159-163. |
| [11] | LIU Yu, YAN Lan, JIANG Yuan-ying. Study on the mechanism of NT-89 against Candida albicans based on quantitative proteomics [J]. Chinese Journal of Mycology, 2019, 14(2): 70-77. |
| [12] | . [J]. Chinese Journal of Mycology, 2019, 14(2): 124-128. |
| [13] | DENG Jie-hua, LI JI-hong, QI Xiao-ming, WANG Gang-sheng. Comparison of sensitivity of cinnamaldehyde and caspofungin to Aspergillus oryzae and their effects on cell wall of Aspergillus fumigatus [J]. Chinese Journal of Mycology, 2018, 13(6): 345-349. |
| [14] | . [J]. Chinese Journal of Mycology, 2018, 13(6): 354-356. |
| [15] | SHANG Pan-pan, WANG Ai-ping. Safety analysis of itraconazole clinical application [J]. Chinese Journal of Mycology, 2018, 13(6): 376-379. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
